Adial Pharmaceuticals, Inc.
- Open
- 5.89
- Day high
- 5.98
- Day low
- 5.30
- Prev close
- 5.60
- Volume
- 70K
- Mkt cap
- $17M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 108.1
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $106K over the last 3 months (6 open-market buys, 0 sales)
- 🏛Institutions reducing (13F)
Adial Pharmaceuticals, Inc. (ADIL) is a Healthcare company listed on NASDAQ. The stock is down 39% over the past year. Over the trailing 3 months, insiders filed 6 open-market buys and 0 sales (SEC Form 4).
Adial Pharmaceuticals, Inc. (ADIL) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ADIL earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 12, 2026 | $-1.03 | $-11.25 | -992.2% | — | — |
| May 8, 2026 | $-2.73 | $-1.48 | +45.8% | — | — |
| Mar 10, 2026 | $-2.13 | $-3.75 | -76.1% | — | — |
| Nov 13, 2025 | $-2.25 | $-2.00 | +11.1% | — | — |
| Aug 13, 2025 | $-0.22 | $-0.18 | +18.2% | — | — |
| May 14, 2025 | $-0.50 | $-0.34 | +32.0% | — | — |
| Mar 4, 2025 | $-0.38 | $-0.15 | +60.5% | — | — |
| Apr 4, 2024 | $-0.76 | $-1.35 | -77.6% | — | — |
| Nov 14, 2023 | $-1.14 | $-1.14 | +0.0% | — | — |
| Aug 21, 2023 | $-1.50 | $-1.33 | +11.3% | — | — |
| May 12, 2023 | $-3.50 | $-2.75 | +21.4% | — | — |
| Nov 14, 2022 | $-4.50 | $-3.00 | +33.3% | — | — |
ADIL insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 16, 2026 | Coastlands Capital LP10 percent owner | Buy | 1,233 | $2.75 |
| Jul 16, 2026 | Coastlands Capital LP10 percent owner | Buy | 2,000 | $2.65 |
| Jul 13, 2026 | Coastlands Capital LP10 percent owner | Buy | 10,053 | $2.79 |
| Jul 13, 2026 | Coastlands Capital LP10 percent owner | Buy | 1,700 | $2.70 |
| Jul 1, 2026 | Coastlands Capital LP10 percent owner | Buy | 25,000 | $2.60 |
| Jun 16, 2026 | Davidson Mattdirector, officer: Chief Development Officer | Grant | 61,647 | — |
| Jun 16, 2026 | Young Wendy B.director | Buy | 36,378 | $0.00 |
| Jun 16, 2026 | Davidson Mattdirector, officer: Chief Development Officer | Grant | 101 | — |
| Jun 16, 2026 | Davidson Mattdirector, officer: Chief Development Officer | Grant | 1,822 | — |
| Jun 16, 2026 | Davidson Mattdirector, officer: Chief Development Officer | Grant | 232,417 | — |
| Jun 16, 2026 | Davidson Mattdirector, officer: Chief Development Officer | Grant | 3,427 | — |
| Apr 9, 2026 | Schuyler Kevindirector | Grant | 9,185 | — |
| Apr 9, 2026 | Shah Vinayofficer: Chief Financial Officer | Grant | 17,325 | — |
| Apr 9, 2026 | Gilliland Robertson H.director | Grant | 9,185 | — |
| Apr 9, 2026 | Claiborne Cary Jdirector, officer: Chief Executive Officer | Grant | 37,985 | — |
Source: ADIL SEC Form 4 filings, latest Jul 16, 2026. For informational purposes only — not investment advice.
See the full ADIL insider & 13F page →Adial Pharmaceuticals, Inc. company profile
Overview
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Charlottesville, Virginia. The company went public in July 2018 and focuses on developing therapeutic treatments for addiction and related disorders. Adial is currently advancing its lead drug candidate through late-stage clinical trials, representing a specialized approach to addressing substance use disorders through targeted pharmaceutical interventions.
Business
Adial Pharmaceuticals operates in the biotechnology sector, specifically focusing on developing treatments for addiction medicine. The company's core business revolves around discovering, developing, and commercializing pharmaceutical therapies that target addiction and related behavioral disorders. The company's primary product candidate is AD04, a selective serotonin-3 (5-HT3) receptor antagonist currently in Phase III clinical trials for treating alcohol use disorder (AUD). Serotonin-3 receptors are proteins found in the brain and other parts of the nervous system that play a role in various neurological functions, including mood regulation and addiction pathways. By blocking these specific receptors, AD04 aims to reduce alcohol cravings and consumption in patients with alcohol use disorder. Alcohol use disorder is a medical condition characterized by an inability to control alcohol consumption despite negative consequences. It affects millions of people worldwide and represents a significant public health challenge. Current treatment options are limited, creating a substantial market opportunity for effective new therapies. Beyond AD04, Adial is also exploring the development of additional drug candidates for non-opioid pain management and other diseases and disorders, though these programs appear to be in earlier stages of development compared to their lead alcohol use disorder treatment.
Revenue model
As a clinical-stage biopharmaceutical company, Adial Pharmaceuticals currently generates no revenue from product sales, as evidenced by zero revenue reported across all recent quarters. The company operates on a research and development model typical of early-stage biotech firms, where value creation comes from advancing drug candidates through clinical trials toward regulatory approval and eventual commercialization. The company's future revenue model will likely center on product sales of AD04 and other approved therapies, potentially supplemented by licensing agreements, partnership deals, or royalty arrangements with larger pharmaceutical companies. Biotech companies often enter into strategic partnerships where they receive upfront payments, milestone payments during development, and royalties on future sales in exchange for development or commercialization rights. Currently, Adial funds its operations through equity financing, as indicated by its cash reserves and absence of significant debt. The company's financial sustainability depends on successfully advancing AD04 through Phase III trials and securing regulatory approval, which would enable revenue generation through product sales. Several factors could significantly impact the company's future profitability. Success in clinical trials and regulatory approval would dramatically improve the revenue outlook, while clinical failures could severely impact the company's prospects. The competitive landscape for addiction treatments, pricing pressures from healthcare payers, and the ability to achieve market penetration will all influence future margins. Additionally, the company's burn rate and ability to secure additional funding during the lengthy drug development process represent critical financial considerations.
Competitive moat
Adial Pharmaceuticals operates in a challenging competitive environment with limited sustainable moats typical of clinical-stage biotech companies. The company's primary competitive advantage lies in its specialized focus on addiction medicine and the potential first-mover advantage if AD04 successfully reaches market as an effective treatment for alcohol use disorder. The company's intellectual property portfolio around AD04 and its specific mechanism of action (5-HT3 receptor antagonism for addiction treatment) provides some protection, though the strength and duration of this protection depends on patent scope and expiration dates. The specialized nature of addiction medicine and the regulatory expertise required to navigate clinical trials in this therapeutic area creates modest barriers to entry. However, the company faces significant competitive risks. Large pharmaceutical companies with substantially greater resources could develop competing treatments or acquire promising competitors. The biotech sector is highly competitive, with numerous companies pursuing various approaches to addiction treatment. Additionally, the company's single-asset focus on AD04 creates concentration risk - clinical failure would severely impact the company's competitive position. The regulatory environment presents both opportunities and challenges. While FDA approval would provide market exclusivity, the lengthy and expensive clinical trial process creates vulnerability to well-funded competitors who might advance alternative treatments more quickly. Overall, Adial's moat appears relatively narrow, dependent primarily on execution excellence and the successful clinical development of AD04.
Risks & safety
Adial Pharmaceuticals presents significant financial risks typical of clinical-stage biotech companies, with limited margin of safety for investors. • **Cash Position**: The company maintains approximately $2.4 million in cash and short-term investments as of Q1 2025, down from $3.8 million at the end of 2024, indicating rapid cash depletion. • **Burn Rate**: Operating cash flow losses of approximately $1.6 million in Q1 2025 and $6.9 million for full year 2024 suggest a quarterly burn rate of around $1.7 million, providing less than four quarters of runway at current spending levels. • **Debt Level**: The company maintains minimal debt with a debt-to-equity ratio near zero, reducing financial leverage risk but also indicating limited access to debt financing. • **Valuation Metrics**: Trading at a price-to-book ratio of 5.5x and negative earnings metrics, the stock appears expensive relative to tangible assets. • **Solvency Risk**: With current assets of $2.6 million against current liabilities of $1.3 million, the company maintains a current ratio of approximately 2.0x, providing short-term liquidity but insufficient for long-term operations without additional financing. • **Additional Considerations**: The company will likely need to raise additional capital within the next 12 months to continue operations and complete clinical trials, creating potential dilution risk for existing shareholders.
Recent development
Based on the available financial data, Adial Pharmaceuticals has maintained focus on advancing its lead candidate AD04 through clinical development. The company's consistent zero revenue across all reporting periods indicates continued investment in research and development activities rather than pivoting toward revenue-generating activities. The company's cash management appears to be a critical strategic consideration, with cash reserves declining from approximately $4.0 million in mid-2022 to $2.4 million in Q1 2025. This trajectory suggests the company has been actively funding clinical trial activities and operational expenses while working toward completing Phase III trials for AD04. The steady quarterly losses ranging from $2.0 million to $2.5 million per quarter indicate consistent investment in clinical development activities. The company's ability to maintain operations while advancing its clinical programs suggests disciplined cash management, though the declining cash position indicates the need for additional financing to complete development milestones. Without detailed earnings call transcripts, specific strategic initiatives, partnership developments, or clinical trial updates cannot be detailed, but the financial trajectory suggests continued focus on the core AD04 development program while managing cash resources to extend operational runway.
ADIL company profile · for informational purposes only — not investment advice.
Track ADIL with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free